ArticleJournal of surgical oncology2026
Pelvic MRI Following Total Neoadjuvant Therapy for Rectal Cancer Poorly Predicts a Complete Clinical Response.
Article in Journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveDetermining complete clinical response (cCR) after total neoadjuvant therapy (TNT) for the treatment of rectal cancer remains challenging. Post-treatment restaging can show discordant results between endoscopy and pelvic MRI. The aim of this study was to assess the outcomes of patients that had an endoscopic cCR upon restaging, but showed continued radiographical disease.
methodsThis is a retrospective study of rectal cancer patients treated at UChicago (2015-2022). Patients who received TNT, had a cCR on restaging endoscopy, and pursued nonoperative management (NOM) were included. Outcomes between patients with residual or no residual disease on restaging MRI were compared.
resultsThirty patients were endoscopically negative on restaging and entered NOM. Of these, restaging MRI showed residual disease in 12 (40%) patients and no residual disease in 18 (60%) patients. After a mean follow-up of 4.8 years, nine patients (30%) experienced regrowth. There was no difference in regrowth rates between patients with negative versus positive restaging MRI (33% vs. 27.8%; p = 0.75). After a mean of 4.0 years, 67% of patients who had an initial positive restaging MRI did not develop a regrowth.
conclusionTwo-thirds of endoscopically negative patients with initially positive restaging MRIs showed no regrowth after 4 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.